Fertility and pregnancy in the patient with inflammatory bowel disease

Mahadevan, U.
August 2006
Gut;Aug2006, Vol. 55 Issue 8, p1198
Academic Journal
The article presents information on studies conducted on pregnant inflammatory bowel disease patients related to their issues of fertility, effects and their chemotherapy. Commonly, most inflammatory bowel disease patients are affected during their most productive period. While treating bowel disease patients, doctors focus on the remission of the disease, then the focus shifts towards the conception of a healthy child. The effects and medications of ulcerative colitis and fertility are presented.


Related Articles

  • Double administration of mesalazine cost saving in UC.  // PharmacoEconomics & Outcomes News;12/1/2007, Issue 542, p8 

    The article focuses on the results of a study which found that combination therapy with mesalazine given both orally and as an enema preparation seems to be more cost effective compared with oral mesalazine alone in patients with mild-to-moderate active ulcerative colitis (UC). It states that...

  • Rituximab.  // Reactions Weekly;1/12/2008, Issue 1184, p30 

    The article describes the case of a 58-year-old man who developed an exacerbation of ulcerative colitis during treatment with rituximab salvage therapy. An overview of the clinical history of the patient is presented, as well as a discussion on the physical and laboratory examinations performed...

  • Conception, fertility and pregnancy in women with infl ammatory bowel disease. Hagen-Hurley, Tina // Gastrointestinal Nursing;May2008, Vol. 6 Issue 4, p34 

    An estimated 160 people in every 100 000 are affected by ulcerative colitis (UC), while Crohn's disease (CD) is found in approximately 50 in 100 000 (British Society of Gastroenterolgy (BSG), 2003). Although men and women are equally affected, the fact that inflammatory bowel disease (IBD)...

  • Worries and Concerns among Inflammatory Bowel Disease Patients Followed Prospectively over One Year. Jelsness-Jørgensen, Lars-Petter; Moum, Bjørn; Bernklev, Tomm // Gastroenterology Research & Practice;2011, Vol. 2011, p1 

    Disease-related worries are frequently reported in inflammatory bowel disease (IBD), but longitudinal assessments of these worries are scarce. In the present study, patients completed the rating form of IBD patient concerns (RFIPC) at three occasions during one year. One-way analysis of variance...

  • RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL OF ORAL ALOE VERA GEL FOR MILD--MODERATELY ACTIVE ULCERATIVE COLITIS. Langmead, L.; Feakins, R. M.; Goldthorpe, S.; Hott, H.; Tsironi, E.; de Silva, A.; Jewell, D. P.; Rampton, D. S. // Gut;Apr2004 Supplement 3, Vol. 53, pA30 

    The herbal preparation aloe vera has been claimed to have anti-inflammatory effects and, despite a lack of evidence of its therapeutic efficacy, is widely used by patients with inflammatory bowel disease. Oral aloe vera taken for 4 weeks produces a clinical response more often than placebo, it...

  • PREVALENCE OF SPONDYLOARTHROPATHY IN PUERTO RICAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. Rodriguez, Vanessa E.; Costas, Pablo J.; Vazquez, Maria; Alvarez, Gilberto; Perez-Kraft, Gladys; Climent, Consuelo; Nazario, Cruz Maria // Ethnicity & Disease;Spring2008 Supplement2, Vol. 18, p2:225 

    Introduction: Inflammatory arthritis is the most common extraintestinal manifestation in patients with inflammatory bowel disease (IBD). Approximately 20% of all IBD patients will present with peripheral arthritis, sacroiliitis, or spondylitis. The purpose of this study was to determine the...

  • Management of inflammatory bowel disease in poor responders to infliximab. Guerra, Iván; Bermejo, Fernando // Clinical & Experimental Gastroenterology;2014, Vol. 7, p359 

    Infliximab (IFX) is an effective treatment for inducing and maintaining response in Crohn's disease and ulcerative colitis patients. Some patients present lack of response or loss of response to IFX during maintenance therapy. Empirical management with combination therapy with an...

  • How Important is Onset of Action in Ulcerative Colitis Therapy? Masson, Steven; Nylander, David; Mansfield, John C. // Drugs;2005, Vol. 65 Issue 15, p2069 

    Pharmacotherapy is the cornerstone of management in ulcerative colitis. However, controversy remains over optimal medical strategies. Specifically, differences in the onset of action of various drug therapies are thought to influence the achievement and maintenance of remission of disease, yet...

  • Strong Protective Effect of DR3 Against Ulcerative Colitis in the Spanish Population. Gómez-García, María; Oliver, Javier; Márquez, Ana; Mendoza, Juan L.; López-Nevot, Miguel Ángel; Fernández-Arquero, Miguel; González-Escribano, María F.; Díaz-Rubio, Manuel; Concha, Emilio G. de la; Urcelay, Elena; Martín, Javier; Martínez, Alfonso // American Journal of Gastroenterology;Dec2007, Vol. 102 Issue 12, p2762 

    OBJECTIVES: Ulcerative colitis (UC) is a chronic inflammatory disease affecting the colon. Major histocompatibility complex (MHC) on the short arm of human chromosome 6 has been thoroughly studied as a susceptibility locus. However, one of the strongest MHC associations found, that of HLA-DR3...


Read the Article


Sign out of this library

Other Topics